Company Filing History:
Years Active: 2024
Title: Innovations by Jiajia Pan in Cancer Treatment
Introduction
Jiajia Pan is an accomplished inventor based in Rockville, MD (US). He has made significant contributions to the field of cancer research, particularly through his innovative work on monoclonal antibodies. His research focuses on developing targeted therapies for pancreatic cancer and other malignancies.
Latest Patents
Jiajia Pan holds a patent for "High affinity monoclonal antibodies targeting glypican-1 and methods of use." This patent describes monoclonal antibodies that specifically bind to glypican-1 (GPC1). The invention also includes chimeric antigen receptor (CAR) T cells, immunotoxins, and other antibody conjugates based on the GPC1-specific antibodies. These advancements can be utilized in the diagnosis and treatment of GPC1-positive pancreatic cancer and other cancers.
Career Highlights
Jiajia Pan is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to contribute to groundbreaking research in immunotherapy and cancer treatment.
Collaborations
Some of Jiajia Pan's notable coworkers include Mitchell Ho and Nan Li. Their collaborative efforts have further advanced the research and development of innovative cancer therapies.
Conclusion
Jiajia Pan's contributions to the field of cancer research through his patented innovations highlight the importance of targeted therapies in modern medicine. His work continues to pave the way for new treatment options for patients suffering from cancer.